Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC

Video

Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.

Xiuning Le, MD, PhD, an assistant professor of thoracic/head and neck medical oncology, Division of Internal Medicine, at The University of Texas MD Anderson Cancer Center, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR- or HER2-positive exon 20–mutant non–small cell lung cancer (NSCLC).

The agent was examined in the phase 2 ZENITH20 trial (NCT03318939), which administered poziotinib twice daily in patients with EGFR- or HER2-positive exon 20–mutant NSCLC, according to Le. This trial had numerous arms, with cohort 2 focused on patients with HER2-positive exon 20 disease who had received prior therapies. Patients in this cohort experienced an objective response rate of 27.8%.

The next steps for poziotinib involve going through the FDA fast-track process, Le says. By optimizing the treatment regimen, it is possible to provide patients with a better quality of life, as well as keep them on the drug longer, which may potentially improve efficacy. Through this, it is possible that more patients, including those who are EGFR positive, may benefit from treatment with poziotinib, Le concludes.

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania